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Abstract Type 1 diabetes is an immune-mediated disease
leading to almost total beta cell destruction and permanent
exogenous insulin dependency. The appearance of clinical
symptoms is preceded by an asymptomatic preclinical period,
the duration of which is highly individual. The emergence of
diabetes-associated autoantibodies into the peripheral circula-
tion is the first detectable sign of beta cell autoimmunity. If
type 1 diabetes is diagnosed in childhood the preclinical peri-
od lasts for an average of 2.5–3 years, but clinical symptoms
may in some cases appear within a few months or be delayed
for more than 20 years. In this issue of Diabetologia,
Bonifacio and colleagues (doi:10.1007/s00125-016-4144-8)
suggest that asymptomatic beta cell autoimmunity should be
considered as a pathological and diagnostic entity. Although
such a strategy may have some positive consequences, it might
also have serious drawbacks. To label an asymptomatic child
that may have 10–20 years of a healthy life ahead of him/her as a
patient will most likely affect both the life of the family and the
child. Therefore, we think that one should not adapt the new
diagnosis before the psychological consequences of such a
strategy have been assessed. Instead, since metabolic abnormal-
ities precede the appearance of clinical symptoms of type 1
diabetes, analysis of a combination of immunological and meta-
bolic markers will provide better insight into the likelihood of
progression to clinical disease, with a shorter ‘sickness’ period.
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Is it justified to label an asymptomatic
autoantibody-positive child as a patient?
The position paper by Bonifacio et al argues that asymptom-
atic beta cell autoimmunity should be perceived as a disorder,
representing a true diagnosis reflective of a medical condition
[1]. This is a controversial proposal that needs broad discus-
sion and thorough consideration among researchers, clini-
cians, healthcare authorities and affected families. The most
critical issue, in our view, is whether it is justified to label an
asymptomatic child with a normal glucose tolerance as a pa-
tient with a disease. We are aware that the overwhelming
majority of young children who test persistently positive for
two or more beta cell autoantibodies will eventually present
with clinical type 1 diabetes [2]. However, a proportion of
such children will experience one or more inverse seroconver-
sions [3]. According to The Environmental Determinants of
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Diabetes in the Young (TEDDY) study, that proportion was
only 1.4% when including genetically predisposed children
who tested persistently positive (in at least two sequential
samples) for multiple biochemical autoantibodies [3], but in
the Type 1 Diabetes Prediction and Prevention (DIPP ) study
9.3% of children with HLA-conferred disease susceptibility
who had two or more autoantibodies on at least two occasions
experienced an inverse seroconversion (J. Selvenius, R. Veijola,
H. Siljander, M. Knip, unpublished data). Such children have a
clearly reduced risk of progression to clinical type 1 diabetes
(Fig. 1). This suggests that a nontrivial proportion of children
testing positive for multiple autoantibodies with low progression
risk would be labelled as being sick. Moreover, the suggested
abbreviation of autoimmune beta cell disorder (ABCD)
is already used for other conditions, such as peroxisome
dysfunction disorders [4].
It is not possible to predict when type 1 diabetes will
manifest based on the autoantibody status, and, as previously
mentioned, the interval from seroconversion to the appearance
of clinical symptoms may last for more than 20 years [5].
Accordingly an asymptomatic autoantibody-positive individual
may remain normoglycaemic and healthy, whilst carrying the
patient label for several decades. What will the psychological
consequences be? How will the family react to this and
how will the children themselves handle the situation?
More information and experience is needed regarding
these issues, including recommendations for clinical
follow-up and psychological support for these families.
Pros and cons of the autoimmune beta cell disorder
concept
We think that the proposal by Bonifacio et al is premature,
since there are still many questions and open issues around the
cause and disease process in type 1 diabetes.We are afraid that
their proposal would result in a scenario where asymptomatic
autoantibody-positive children with normal glucose tolerance
are labelled as patients, although they may have a healthy life
for many years ahead of diagnosis. We do not know the con-
sequences of the patient label on the child and his/her family.
At least, the consequences of the patient label should be stud-
ied before going forward. Our long-term experience from
large prospective clinical studies suggests that families with
a child persistently positive for multiple beta cell autoanti-
bodies can be informed about the significance of this finding
by using various stages of type 1 diabetes, which have been
published recently [6]. Stage 1 indicates a presymptomatic/
preclinical stage with beta cell autoimmunity; stage 2, beta
cell autoimmunity and dysglycaemia; and stage 3, symptom-
atic type 1 diabetes. The same ICD-10 code (endocrine, nutri-
tional and metabolic diseases (E)10: Type 1 diabetes) can be
used for all of these stages; thus, a new disease code would be
unnecessary. Instead of a new diagnosis we would, therefore,
prefer the well-accepted concept of subclinical disease states
for type 1 diabetes. This is already widely used for conditions
such as infections and malignancies. This concept would also
take into account the fact that progression time to clinical
disease varies between individuals and may last for several
years or even decades. In addition, there would be the possi-
bility that no progression to clinical disease may occur, which
may be relevant for those with multiple islet autoantibodies
but no signs of dysglycaemia.
Bonifacio et al state that making the diagnosis in the
asymptomatic stage, prior to clinical manifestation, has the
potential to reduce the threat of ketoacidosis, alleviate psycho-
logical burden, allow for earlier initiation of experimental
treatments that may preserve insulin sufficiency and reduce
healthcare costs. A closer analysis of these arguments shows
that some are well justified, whereas others are not. There are
several reports showing that participation in prospective stud-
ies with sequential autoantibody testing substantially reduces
the frequency of diabetic ketoacidosis at diagnosis in those
who present with clinical diabetes [7, 8]. As far as we are
aware, there are no studies suggesting that an early diagnosis
of type 1 diabetes reduces the psychological burden related to
the clinical disease. Increased anxiety and worry are common
reactions among parents when learning that their child is at
increased risk for type 1 diabetes [9]. In most cases these
reactions dissipate with time but some parents may be partic-
ularly vulnerable to prolonged anxiety or depression. In con-
trast with the early detection of other diseases, such as rheu-





































Follow-up after the initial seroconversion (years)
Fig. 1 Progression to clinical type 1 diabetes among 55 children who
tested positive for at least two autoantibodies and experienced an inverse
seroconversion after persistent multipositivity (blue line) compared with
the 537 remaining participants who were positive for multiple autoantibodies
during the whole follow-up time (red line). p<0.001, Kaplan–Meier survival
analysis
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the symptoms, although they do not cure the disease [10], it
seems ethically questionable to cause such anxiety without
any means of relieving it by offering preventive treatment.
So far there is no effective and safe experimental treatment
capable of preserving insulin secretion to such an extent that a
child with diabetes-related autoantibodies remains free of the
need for exogenous insulin.
Beta cell autoimmunity vs insulitis
Regarding type 1 diabetes, there is likely consensus that the
disease is an immune-mediated disorder but not necessarily an
autoimmune disease. It may, for example, be an infectious
disease. Available data from autoantibody-positive organ
donors suggest that there is a lack of correlation between
the number of detectable autoantibodies in peripheral
blood and signs of ongoing disease in the pancreatic islets
[11, 12]. In a Belgian study on 62 autoantibody-positive
donors, insulitis was observed in two donors, both having
multiple diabetes-associated autoantibodies and a high-
risk HLA genotype [11]. Another study, using donors from
the Nordic Network for Islet Transplantation, identified 32
autoantibody-positive individuals, nine of whom had multiple
autoantibodies, all without any signs of insulitis [12]. We
know that the presence of multiple autoantibodies is associat-
ed with a substantially higher risk of progression to overt
disease than positivity for a single autoantibody. The data
available showing a weak association between autoantibody
positivity and insulitis in the target organ [12], however, makes
it challenging to argue that humoral beta cell autoimmunity
would represent a pathological entity or disease.
Combination of autoimmune and metabolic markers
Given that the proposed new diagnosis of ABCD for
asymptomatic individuals with two or more beta cell auto-
antibodies [1] is associated with a series of limitations and
drawbacks, one may prefer staging of asymptomatic or sub-
clinical type 1 diabetes based on both autoimmune and
metabolic findings. Based on data from the DIPP study,
we have shown that dysglycaemia precedes the clinical di-
agnosis of type 1 diabetes, with a considerably shorter in-
terval period than that from the time of seroconversion to
the appearance of clinical symptoms [13, 14]. A 10% rise in
the HbA1c levels in samples obtained 3–12 months apart
predicted the diagnosis of clinical disease after a median
time of 1.1 years from the observed rise in HbA1c. Also,
where the HbA1c level was ≥5.9% (41 mmol/mol) in two
consecutive samples, the median time to diagnosis was
0.9 years [13]. Furthermore, impaired fasting glucose
(IFG) and impaired glucose tolerance (IGT), as defined by
WHO [15], are definite risk factors for type 1 diabetes, as
is a random plasma glucose value ≥7.8 mmol/l [14]. The
median time to diagnosis after the detection of IFG was
5.2 years, after IGT, 0.7 years and after a random plasma
glucose ≥7.8 mmol/l, 1.0 years. In a retrospective analysis
both the OGTT-derived 2 h plasma glucose concentration
and random plasma glucose level started to increase
1.5 years before diagnosis. These observations indicate that
ametabolic diagnosis of asymptomatic diabetes reduces the risk
of diabetic ketoacidosis as effectively as the proposed ABCD
diagnosis but shortens the ‘sickness’ period considerably. The
limitation of this metabolic diagnosis is a relatively modest
sensitivity for clinical diabetes, ranging from only 6% for IFG
to 57% for a 10% increase in HbA1c over 3–12 months. New
approaches, such as continuous glucose monitoring (CGM),
which provides information about glycaemic variability,
may be useful tools in future studies and in the assessment
of children with persistent beta cell autoimmunity.
Currently there is no effective treatment to reverse or delay
the progression of beta cell autoimmunity. If such a treatment
becomes available, the scenario would change dramatically
and the indication for use of such treatment would be persistent
positivity for multiple islet autoantibodies. However, for the
time-being, using a combination of autoimmune and
metabolic markers, may better serve to assess disease
status in asymptomatic individuals than the introduction
of the ABCD concept.
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